| The exciting new field of HER2-low breast cancer treatment D Eiger, E Agostinetto, R Saúde-Conde, E de Azambuja Cancers 13 (5), 1015, 2021 | 142* | 2021 |
| Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors M Brandao, R Caparica, D Eiger, E de Azambuja Annals of oncology 30, x27-x42, 2019 | 75 | 2019 |
| Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer … J Huober, CH Barrios, N Niikura, M Jarząb, YC Chang, ... Journal of Clinical Oncology 40 (25), 2946-2956, 2022 | 60 | 2022 |
| Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center BL Prado, DBD Gomes, PLS Usón Júnior, P Taranto, MS França, D Eiger, ... BMC Palliative Care 17, 1-7, 2018 | 49 | 2018 |
| Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials E Agostinetto, D Eiger, M Lambertini, M Ceppi, M Bruzzone, N Pondé, ... European Journal of Cancer 148, 76-91, 2021 | 37 | 2021 |
| Emerging therapeutics for patients with triple-negative breast cancer E Agostinetto, D Eiger, K Punie, E de Azambuja Current oncology reports 23, 1-14, 2021 | 36 | 2021 |
| Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab treatment optimization trial D Eiger, NF Pondé, D Agbor-Tarh, A Moreno-Aspitia, M Piccart, ... British journal of cancer 122 (10), 1453-1460, 2020 | 32 | 2020 |
| VP6-2021: IMpassion050: a phase III study of neoadjuvant atezolizumab+ pertuzumab+ trastuzumab+ chemotherapy (neoadj A+ PH+ CT) in high-risk, HER2-positive early breast cancer … J Huober, CH Barrios, N Niikura, M Jarzab, YC Chang, ... Annals of Oncology 32 (8), 1061-1062, 2021 | 31 | 2021 |
| Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy MA Franzoi, D Eiger, L Ameye, N Ponde, R Caparica, C De Angelis, ... JNCI: Journal of the National Cancer Institute 113 (4), 462-470, 2021 | 24 | 2021 |
| Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors MA Franzoi, C Vandeputte, D Eiger, R Caparica, M Brandão, ... Breast cancer research and treatment 181, 199-209, 2020 | 24 | 2020 |
| Impact of HIV infection on baseline characteristics and survival of women with breast cancer M Brandão, M Bruzzone, MA Franzoi, C De Angelis, D Eiger, R Caparica, ... Aids 35 (4), 605-618, 2021 | 21 | 2021 |
| Pertuzumab in HER2-positive early breast cancer: current use and perspectives D Eiger, NF Pondé, E de Azambuja Future Oncology 15 (16), 1823-1843, 2019 | 20 | 2019 |
| Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial A De Caluwé, L Buisseret, P Poortmans, D Van Gestel, R Salgado, ... BMC cancer 21, 1-9, 2021 | 17 | 2021 |
| Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials D Eiger, MA Franzoi, N Pondé, M Brandão, C De Angelis, MS Nogueira, ... ESMO open 5 (1), e000659, 2020 | 17 | 2020 |
| 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line … D Eiger, C Maurer, M Brandao, PG Aftimos, K Punie, D Taylor, ... Annals of Oncology 31, S386-S387, 2020 | 14 | 2020 |
| BERENICE final analysis: Cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early … C Dang, MS Ewer, S Delaloge, JM Ferrero, R Colomer, ... Cancers 14 (11), 2596, 2022 | 11 | 2022 |
| Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: A critical review D Eiger, DA Oliveira, RL Oliveira, MC Sousa, MDC Brandão, ... Anais brasileiros de dermatologia 93 (4), 553-558, 2018 | 9 | 2018 |
| Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial E de Azambuja, E Agostinetto, M Procter, D Eiger, N Pondé, S Guillaume, ... ESMO open 8 (1), 100772, 2023 | 8 | 2023 |
| The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC) D Eiger, M Wagner, NF Pondé, MS Nogueira, L Buisseret, E de Azambuja Acta Oncologica 59 (6), 723-725, 2020 | 8 | 2020 |
| Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: an 11-year single institutional experience MA Franzoi, R Saúde-Conde, SC Ferreira, D Eiger, A Awada, ... The Breast 57, 86-94, 2021 | 7 | 2021 |
Noam Falbel PondéIQVIA Biotech, Morrisville, NC, USAVerified email at iqvia.com
